Cort Johnson om Rituximab studiet på Haukeland Sykehus
Hentet fra aboutmecfs.org:
«Could the first drug for ME/CFS be a chemotherapeutic drug? That would sound like a long shot at best but the fact is a two physicians in Norway are having surprising success with a drug originally developed to treat cancer.
Their Story – Dr. Fluge and Dr. Olav Mella of Haukeland University Hospital in Bergen, Norway, began their investigation of Rituximab’s effects on CFS after treating several Hodgkin’s Lymphoma patients who had long standing cases of CFS prior to developing cancer.
To the doctors’ (and the patients!) surprise the three people with ME/CFS reported they began experiencing significant improvement in their ME/CFS symptoms some 6-12 (16) weeks after completing their chemotherapy regimen. The significant effects lasted up to six to 16 weeks with benefits still present at 6 months. Eventually, however, they relapsed. A second trial resulted in a similar pattern of increased health, this time of a bit longer duration followed again, by a relapse. A third course in two patients evoked a similar pattern.
These successes prompted the physicians to begin a small 30 person Phase II double-blinded placebo controlled trialwhich began in June 2008 and ended in June 2010. (Phase II trials analyze safety and efficacy) »
Les mer HER
Les på norsk med Google Translater HER
Du kan også høre hva Mella forteller om studiet i intervjuet på «Verdt å vite» 14.12 eller lese det i transkripsjonen HER